Stock Screener App

Frei -

Installieren

39.00

2.24% -0.768

Parabilis Medicines Inc (PBLS)

Überblick Nachrichten Preisverlauf Forum Prognose

Parabilis Medicines Inc Aktie (PBLS) Neueste Nachrichten

1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - MarketBeat

Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine

PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Barchart.com

ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat

Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat

1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC - MarketBeat

venBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat

Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS - MarketBeat

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Parabilis appoints Craig Tendler to its Board and Science & Technology Committee - TradingView

Parabilis Medicines adds former J&J oncology executive to board By Investing.com - Investing.com Canada

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - Yahoo Finance

ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat

Parabilis Medicines Price Insights - YCharts

Top Parabilis Medicines (PBLS) Competitors 2026 - MarketBeat

Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat

Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat

symbol__ Stock Quote Price and Forecast - CNN

Biotech’s reverse merger renaissance poised to continue - Endpoints News

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail

Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo

Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan

BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha

PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus

Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat

Parabilis Medicines: Q2 Earnings Snapshot - AOL.com

Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan

Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria

PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com

Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com

Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView

Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times

Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative

Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year HighWhat's Next? - MarketBeat

Parabilis Medicines Ord Shs (PBLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Parabilis Medicines, Inc.Common Stock (Nasdaq:PBLS) Stock Quote - The Chronicle-Journal

Alphabet Reports Share Stake In SpaceX, Fervo Energy And Parabilis Medicines - TradingView

Parabilis Medicines (PBLS) Institutional Ownership 2026 - MarketBeat

FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS) - Stock Titan

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts - marketbeat.com

PBLS|Parabilis Medicines Ord Shs|Price:31.820|Chg%:+0.540 - TradingKey

Alexis Borisy: Biotech Is Winning the Science and Losing the Story - finance.biggo.com

Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView

Scribe secures $129M in a rare gene editing IPO - BioPharma Dive

Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo

Form 4 Parabilis Medicines For: 22 July - Investing.com India

Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa

RPRX

$60.08

1.14%

INSM

$129.44

3.49%

ROIV

$41.41

0.30%

ALNY

$255.14

1.53%

ONC

$349.34

0.65%

RVMD

$209.18

0.88%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters